New data suggest venetoclax may offset the negative prognostic impact of short telomeres in patients with chronic lymphocytic ...

Pentostatin + cyclophosphamide + rituximab. Phase I dose-finding study in patients with relapsed/refractory CLL (n = 57) [195] 86% ORR in treatment-naive CLL, 17% in relapsed/refractory CLL ...

During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed treatment for a patient with chronic ...

Discover how exercise enhances cancer treatment effectiveness, boosts immunity, and improves patient outcomes with ...

BRUIN CLL-321 serves as the confirmatory trial to ... with pirtobrutinib or investigator's choice of idelalisib-rituximab or bendamustine-rituximab. Patients were mostly enrolled from Europe ...

During a Case-Based Roundtable® event, Catherine Coombs, MD, discussed the BRUIN trial and recent NCCN updates on chronic ...

The results of two controlled trials, now published in the January 2010 issue of Arthritis and Rheumatism, suggest that treatment with the B-cell depleting agent, rituximab, lowers the response to ...

DLBCL: 1400mg/23400 Units over 5mins on Day 1 of Cycles 2–8 of CHOP chemotherapy for up to 7 cycles following a full dose of IV rituximab on Day 1 of Cycle 1. CLL: 1600mg/26800 Units over 7mins ...

As CLL advances into further stages ... Examples of immunotherapy are Rituxan (rituximab), Gazyva (obinutuzumab), and Arzerra ...